[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vascular-aging\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vascular-aging":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,63,90,115,139],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":34,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":62},"100649623","predication-of-arterial-stiffness-in-healthy-adults-by-oral-health-and-chewing-assessments-100649623",false,"NCT07736222","Predication of Arterial Stiffness in Healthy Adults by Oral Health and Chewing Assessments","Oral Structural and Functional Profile as an Additive Biomarker for Explaining Central Arterial Stiffness in the INN.HEALTH Cohort","INNoralHEALTH","Inclusion Criteria:\n\n* adults meeting the INN.HEALTH cohort eligibility criteria, including age ≥18 years, residence in Innsbruck City or Innsbruck-Land, and capacity to consent\n* additionally at Visit 4, participants must report being able to safely chew and, where required, swallow the standardized test materials\n\nExclusion Criteria:\n\n* temporalmandibular joint disorders\n* severe jaw joint complaints\n* active dental treatment at the time of assessment\n* inability to safely chew\u002Fswallow the standardized test materials.",true,"ALL","18 Years",{"count":21,"type":22},750,"ESTIMATED","INTERVENTIONAL",[25],"NA","INN.oral.HEALTH is an sub-study embedded in the Innsbruck Health Promotion Program (INN.HEALTH). The study investigates whether oral health, oral structure, and oral function provide additional information for understanding vascular health in adults from the general population.\n\nCardiovascular and cerebrovascular diseases, such as heart attack and stroke, remain major causes of death and disability. Many risk factors, including blood pressure, blood lipids, blood sugar, smoking, physical activity, sleep, and diet, are already known to influence vascular health. However, oral health may also be related to vascular risk. Conditions such as tooth loss, impaired chewing, reduced tongue strength, or oral disease burden may reflect or contribute to general health and vascular ageing, but their additional value in prevention programs is not yet well understood.\n\nThe main hypothesis of this study is that a standardized oral structure and function profile can improve the explanation of central arterial stiffness beyond established cardiovascular risk factors and lifestyle-related health metrics (INN.HEALTH study). Central arterial stiffness will be assessed using carotid-femoral pulse wave velocity, a marker of vascular ageing and cardiovascular risk.\n\nParticipants will undergo a single oral assessment during Visit 4 of the INN.HEALTH study. The assessment includes screening of oral health status, dentition, bite force, tongue pressure, chewing efficiency, chewing and swallowing performance, questionnaires on oral health-related quality of life and food avoidance, and measurement of masseter muscle thickness. The study does not involve any treatment.\n\nThe results may help clarify whether oral structural and functional markers can contribute to future vascular risk assessment and prevention strategies in the general adult population.",[28,29,30,31,32,33],"Arterial Stiffness","Oral Health","Mastication","Deglutition","Vascular Aging","Cardiovascular Risk",[35,36,37,38,39,40,41,30,42,43,44,45,46,47,48,49],"Carotid-femoral pulse wave velocity","Pulse wave velocity","Central arterial stiffness","Oral health","Bite force","Tongue pressure","Chewing efficiency","Swallowing","Test of Masticating and Swallowing Solids","ToMASS","Food avoidance","Oral health-related quality of life","Masseter muscle thickness","Life's Essential 8","Vascular prevention","RECRUITING","2026-07-27",{"date":53,"type":54},"2026-07-30","ACTUAL",{"date":56,"type":54},"2026-07-08",{"date":58,"type":22},"2027-03-31",{"name":60,"class":61},"VASCage GmbH","OTHER",1,{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":70,"targetDuration":4,"studyType":72,"phases":4,"briefSummary":73,"conditions":74,"keywords":77,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":62},"100649025","vascular-aging-and-acute-kidney-injury-after-cardiac-surgery-100649025","NCT07727772","Vascular Aging and Acute Kidney Injury After Cardiac Surgery","Multidimensional Assessment of Vascular Aging and Its Association With Postoperative Acute Kidney Injury in Patients Undergoing Cardiac Surgery","Inclusion Criteria:\n\n* Adult patients aged 18 years or older.\n* Patients scheduled to undergo cardiac surgery at Nanjing First Hospital, Nanjing Medical University.\n* Patients who are able to provide written informed consent.\n* Patients who are expected to undergo perioperative vascular aging assessment and postoperative renal function monitoring according to the study protocol.\n\nExclusion Criteria:\n\n* Patients younger than 18 years.\n* Patients with preoperative end-stage renal disease or maintenance dialysis.\n* Patients who are unable to complete the study-specified vascular aging assessment.\n* Patients who decline participation or withdraw informed consent.",{"count":71,"type":22},472,"OBSERVATIONAL","This prospective observational cohort study will enroll adult patients undergoing cardiac surgery at Nanjing First Hospital, Nanjing Medical University. The study will evaluate multidimensional vascular aging markers before surgery and assess their association with postoperative acute kidney injury within 7 days after surgery. No intervention will be assigned by the study protocol, and all perioperative management will follow routine clinical practice.",[75,76,32],"Acute Kidney Injury Cardiac Surgery","Postoperative Complications",[78,79,80],"vascular aging","acute kidney injury","postoperative complications","NOT_YET_RECRUITING","2026-07-22",{"date":51,"type":54},{"date":85,"type":22},"2026-07-01",{"date":87,"type":22},"2027-12-28",{"name":89,"class":61},"Nanjing First Hospital, Nanjing Medical University",{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":72,"phases":4,"briefSummary":99,"conditions":100,"keywords":101,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":62},"100638508","snrk--vascular-endothelial-aging-100638508","NCT07591337","SNRK & Vascular Endothelial Aging","The Association Between SNRK and Vascular Endothelial Aging","Inclusion Criteria:\n\n1. Aged 18-80 years, with the capacity to make decisions independently or represented by an authorized legal guardian;\n2. Able to provide complete personal information, medical history, and lifestyle history (e.g., smoking and alcohol consumption history);\n3. No history of severe cardiovascular disease, and deemed eligible for inclusion by a physician.\n\nExclusion Criteria:\n\n1. Women who are pregnant or may become pregnant;\n2. Patients with a history of neurological disorders, tumors, severe cardiovascular or pulmonary disease, liver failure, kidney failure, or blood disorders;\n3. Patients who have undergone carotid stenting, carotid endarterectomy, or other similar procedures, or who have unilateral carotid artery occlusion due to any cause;\n4. Patients who have participated in another clinical trial within the past 4 weeks;\n5. Individuals deemed unsuitable for this clinical trial by the investigators.",{"count":98,"type":22},180,"Cardiovascular diseases pose a serious threat to public health, and their prevalence is on the rise year by year. Vascular aging is an independent risk factor for cardiovascular diseases, and endothelial cell senescence is an early event in vascular aging. Its occurrence can lead to endothelium-dependent vasodilation dysfunction, reduced vascular permeability, and the release of the senescence-associated secretory phenotype (SASP). These vascular pathological changes further damage the vascular media, leading to vascular remodeling and reduced compliance, accelerating the progression of atherosclerosis, and ultimately resulting in cardiovascular diseases such as coronary heart disease and hypertension. Recent research of the investigators has revealed that SNRK, a new member of the AMPK family of cellular energy sensors, plays a key regulatory role in vascular development. Based on this finding, the investigators propose the scientific hypothesis that SNRK responds to both physiological and pathological aging stimuli through differential mechanisms and regulates the process of endothelial cell senescence. In this study, the investigators will explore the correlation between SNRKAS and carotid vascular structure and endothelial function by measuring the levels of the SNRK upstream lncRNA (SNRKAS) in participants' peripheral blood, in conjunction with carotid ultrasound examinations. The findings will provide a solid scientific basis for elucidating new mechanisms underlying the onset and progression of vascular aging and for identifying novel therapeutic targets.",[32],[102,103,104,105,78],"SNRK","carotid atherosclerosis","vascular endothelial cells","cell senescence","2026-05-12",{"date":108,"type":54},"2026-05-15",{"date":110,"type":54},"2026-05-01",{"date":112,"type":22},"2029-04-30",{"name":114,"class":61},"Tianjin Medical University",{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":18,"minAge":122,"maxAge":123,"enrollmentInfo":124,"targetDuration":4,"studyType":23,"phases":126,"briefSummary":127,"conditions":128,"keywords":4,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":62},"100618167","efficacy-and-safety-of-coenzyme-i-for-injection-on-vascular-aging-100618167","NCT07328100","Efficacy and Safety of Coenzyme I for Injection on Vascular Aging.","A Randomized, Double-blind, Parallel Controlled Clinical Trial to Evaluate the Efficacy of Coenzyme I for Injection in the Treatment of Vascular Aging（Pilot Stydy）","Inclusion Criteria:\n\n1. Ages 40-70 years;\n2. cf-PWV was abnormally elevated and above the upper limit of its age-and blood-pressure matched reference range;\n3. Systolic Blood Pressure \\\u003C 160 mmHg and ≥ 140 mmHg or Diastolic BP \\\u003C 100 mmHg ≥ 90mmHg;\n4. Signed informed consent.\n\nExclusion Criteria:\n\n1. Consumption of foods or medications containing high levels of NAD+, NR, NAM, NMN, or niacin-related components (including Vitamin B3 and natural health products) within 3 months prior to screening；\n2. History of major cardiovascular or cerebrovascular events, including myocardial infarction, angina, stroke, or hospitalization for arterial revascularization；\n3. Systolic blood pressure ≥ 160 mmHg and\u002For diastolic blood pressure ≥ 100 mmHg；\n4. Diagnosis of malignant tumor；\n5. Known allergy or history of severe adverse reactions to Coenzyme I injection or any of its components；\n6. History of severe allergies or infusion reactions；\n7. Women who are pregnant, breastfeeding, or planning pregnancy；\n8. Severe hepatic or renal dysfunction: ALT or AST \\> 5 times the upper limit of normal; glomerular filtration rate ≤ 30 mL\u002Fmin\u002F1.73 m²；\n9. Concurrent participation in another clinical trial without completion of the follow-up period；\n10. Other conditions deemed by the investigator as unsuitable for inclusion, such as psychiatric or psychological disorders.","40 Years","70 Years",{"count":125,"type":22},60,[25],"Emerging evidence identifies vascular aging independently predicting cardiovascular events, yet effective clinical interventions remain lacking. Nicotinamide adenine dinucleotide (NAD+) is an essential cofactor whose levels decline with age, and preclinical studies suggest that boosting NAD+ can improve vascular function and structure. Preliminary clinical studies in healthy older adults indicate that supplementation with NAD+ precursors, such as nicotinamide riboside(NR) or nicotinamide mononucleotide (NMN), can reduce arterial stiffness as measured by pulse wave velocity (PWV). However, whether NAD+ supplementation can improve vascular endothelial function and exert anti-stiffening effects in patients who have already developed measurable arterial stiffness remains unknown. Based on this evidence, the investigator hypothesize that the Coenzyme I for Injection will reverse vascular aging in older adults with established arterial stiffening.",[32,129],"NAD","2025-12-28",{"date":132,"type":54},"2026-01-08",{"date":134,"type":22},"2026-01-16",{"date":136,"type":22},"2027-12-31",{"name":138,"class":61},"Shanghai 10th People's Hospital",{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":145,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":18,"minAge":147,"maxAge":148,"enrollmentInfo":149,"targetDuration":4,"studyType":23,"phases":151,"briefSummary":152,"conditions":153,"keywords":4,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":62},"100394279","exclusive-human-milk-in-preterm-neonates-and-early-vascular-aging-risk-factors-neovasc-100394279","NCT04413994","Exclusive Human-milk in Preterm NEOnates and Early VASCular Aging Risk Factors (NEOVASC)","Effects of an Exclusive Human-milk Diet in Preterm NEOnates on Early VASCular Aging Risk Factors (NEOVASC)","NEOVASC","Preterm-born group:\n\nInclusion Criteria:\n\n1. Extremely preterm infants with a birth weight of 500-1250g.\n2. Feeding is NPO or exclusive human milk prior to enrollment.\n3. Parent(s) willing to sign informed consent.-\n\nExclusion Criteria:\n\n1. Infants with a birth weight \\\u003C500g or \\>1250g\n2. Subjects diagnosed with inborn errors of metabolism such as galactosemia, phenylketonuria\n3. Subjects who have not been NPO or fed exclusive human milk diet prior to enrollment.\n4. Presence of major congenital malformation.\n5. Presence of intestinal perforation or Stage 2 Necrotizing enterocolitis prior to enrollment.\n6. Parent(s) not willing to sign informed consent.\n7. Unable to participate for any reason based on the decision of the study investigator (e.g. unlikely to survive the study period).\n\nTerm-born group:\n\nInclusion criteria\n\n1. Term-born children with an adequate birth weight\n2. Parent(s) willing to sign informed consent\n\nExclusion criteria\n\n1. Subjects with acute or chronic illness\n2. Parent(s) not willing to sign informed consent","1 Day","5 Years",{"count":150,"type":22},200,[25],"Early vascular aging has its origins in fetal and neonatal life. The NEOVASC clinical trial aims to determine the effects of an exclusive human milk diet in extremely preterm infants on long-term cardiovascular health.",[154,32],"Prematurity","2025-08-22",{"date":157,"type":54},"2025-08-29",{"date":159,"type":54},"2020-10-09",{"date":161,"type":22},"2028-06-01",{"name":163,"class":164},"Prolacta Bioscience","INDUSTRY"]